Unspecified Adult Solid Tumor, Protocol Specific, Stage IIIC Melanoma, Stage IIIB Melanoma, Stage IIIA Melanoma, Recurrent Melanoma and Stage IV Melanoma Clinical Trial Using dabrafenib, trametinib, navitoclax, pharmacological study and laboratory biomarker analysis

- The folks at National Cancer Institute (NCI) are studying the effects of dabrafenib; trametinib; navitoclax; pharmacological study; laboratory biomarker analysis on Unspecified Adult Solid Tumor, Protocol Specific, Stage IIIC Melanoma, Stage IIIB Melanoma, Stage IIIA Melanoma, Recurrent Melanoma and Stage IV Melanoma in individuals ages 18 years and older. This clinical trial is slated to start October 2013.

Overall Study Contact Info
StatusName Contact Phone
Recruiting

This study is officially titled, "Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma and Other Solid Tumors."

Locations

M D Anderson Cancer Center

Houston, Texas - Recruiting

Cancer Institute of New Jersey

New Brunswick, New Jersey - Recruiting

Massachusetts General Hospital Cancer Center

Boston, Massachusetts - Recruiting

Dana-Farber Cancer Institute

Boston, Massachusetts - Recruiting

Beth Israel Deaconess Medical Center

Boston, Massachusetts - Recruiting

For more study details, please visit this link to ClinicalTrials.gov record, which is the source of this webpage.